High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia.

CONCLUSIONS: The prognostic value of CD56 expression in IR-AML may need to be comprehensively evaluated based on different detection methods, age stratification, countries, treatment options, and other factors. If confirmed, CD56 may be a biomarker for further risk stratification for IR-AML patients. PMID: 33594945 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research